FCM
ANAB icon

Farallon Capital Management’s AnaptysBio ANAB Stock Holding History

Farallon Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-183,876
Closed -$6.16M – 154
2024
Q3 		$6.16M Buy
+183,876
New +$6.28M 0.03% 93
2018
Q1 		– Sell
-561,000
Closed -$56.5M – 89
2017
Q4 		$56.5M Buy
561,000
+315,000
+128% +$23.2M 0.46% 40
2017
Q3 		$8.6M Buy
+246,000
New +$6.64M 0.08% 73

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Farallon Capital Management's ANAB Position: Q4 2024 in Review

Farallon Capital Management sold out of AnaptysBio (ANAB) in Q4 2024, closing a stake of 183,876 shares — an estimated $6.16M sold.

Farallon Capital Management first reported a position in ANAB in Q3 2017 and held it in 3 quarters. The position peaked at $56.5M in Q4 2017. 135 funds tracked by Wall St. Rank hold ANAB as of Q4 2024.

  • Farallon Capital Management reported no remaining AnaptysBio position as of Q4 2024 after selling out during the quarter.
  • Farallon Capital Management sold 183,876 AnaptysBio shares in Q4 2024, an estimated $6.16M.
  • Farallon Capital Management first reported a position in AnaptysBio in Q3 2017 and held it in 3 quarters.
  • Farallon Capital Management's AnaptysBio position peaked at $56.5M in Q4 2017.
  • 135 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2024.

Based on Farallon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.